R3VIVE.ME CJC W/O DAC & IPAMORELIN 20mg Pen
R3vive.me is at the forefront of peptide research and development, focused on advancing the latest innovations in biohacking science. We explore how targeted peptides can support recovery, performance, resilience, and long-term optimization of the human body.
CJC-1295 (Without DAC) & Ipamorelin 20 mg
CJC-1295 (Without DAC) & Ipamorelin is a synergistic peptide combination designed to support the body’s natural pulsatile release of growth hormone. This advanced formulation combines 10 mg of CJC-1295 (Mod GRF 1-29) with 10 mg of Ipamorelin .
Unlike the DAC version, CJC-1295 without DAC has a shorter duration of action, allowing it to more closely mimic the body’s natural growth hormone secretion patterns when administered at appropriate intervals.
Potential Benefits
- Supports lean muscle development and maintenance.
- May aid recovery following exercise and physical activity.
- Promotes healthy tissue repair and regeneration.
- Supports collagen production for skin, connective tissue and joint health.
- May assist with body composition when combined with a healthy diet and regular exercise.
- May contribute to improved sleep quality, which is closely linked to natural growth hormone release.
- Helps support healthy recovery and overall wellbeing.
How It Works
CJC-1295 (without DAC) stimulates growth hormone-releasing hormone (GHRH) receptors, while Ipamorelin selectively activates ghrelin receptors. Together, they encourage the body’s own production of growth hormone rather than supplying growth hormone directly.
Ideal For
- Individuals looking to support recovery from training.
- Those aiming to preserve lean muscle mass.
- People seeking support for healthy ageing and tissue repair.
- Those interested in a more physiological growth hormone release pattern compared with long-acting CJC-1295 with DAC.
Disclaimer: This product is intended for research purposes only. It is not a licensed medicine and is not intended to diagnose, treat, cure or prevent any disease. Any potential benefits described are based on emerging research and should not be interpreted as established clinical outcomes.
R&D professional use and research only purposes